Top entities: Axsome Therapeutics, AXS-12, United States — Food and Drug Administration, Nasdaq.

What category does this event fall under?

Regulatory — classified as regulatory filing.

What is the sentiment of coverage?

Aggregate sentiment score: 15 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This is an active story, last updated Jul 15, 2026. Coverage continues to evolve.

Regulatory regulatory filing

FDA accepts Axsome NDA for AXS-12

Q: When did this event occur?

First reported Jul 15, 2026; last updated Jul 15, 2026.

Q: What is the market impact?

General. The FDA acceptance of the NDA for AXS-12 is a positive regulatory milestone for Axsome Therapeutics, potentially expanding its CNS portfolio.

Analysis based on 13 articles · First reported Jul 15, 2026 · Last updated Jul 15, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The FDA acceptance of the NDA for AXS-12 is a positive regulatory milestone for Axsome Therapeutics, potentially expanding its CNS portfolio. The stock saw a modest premarket increase, reflecting cautious optimism ahead of the May 2027 PDUFA date.

biotechnology pharmaceuticals

Event Summary

Axsome Therapeutics announced that the FDA has accepted its New Drug Application for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy. The FDA set a PDUFA target action date of May 1, 2027, and indicated it does not plan to hold an advisory committee meeting. AXS-12 has orphan drug designation for narcolepsy. Cataplexy affects about 70% of narcolepsy patients, causing sudden muscle weakness triggered by emotions. Axsome shares rose nearly 2% in premarket trading following the announcement.

Entities Involved

stock

Axsome Therapeutics

Axsome Therapeutics is the sponsor of the NDA for AXS-12; FDA acceptance is a positive step toward potential approval, which could add a new revenue stream.

Importance 100.0 Sentiment 15.0

oth

AXS-12

AXS-12 is the drug candidate under review; FDA acceptance advances its path to potential approval for cataplexy in narcolepsy.

Importance 90.0 Sentiment 15.0

govactor

United States — Food and Drug Administration

The FDA accepted the NDA and set a PDUFA date; its decision will determine AXS-12's market entry.

Importance 80.0 Sentiment 0.0

exch

Nasdaq

Axsome is listed on Nasdaq; the event may influence AXSM stock trading.